Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunome, Inc. - Common Stock (NQ:IMNM)

11.34 -0.37 (-3.16%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Immunome, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Infinimmune Announces Research Collaboration with Immunome
From Infinimmune
Via Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From Immunome, Inc.
Via Business Wire
Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update
From Immunome, Inc.
Via Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
Immunome to Present at Upcoming Investor Conferences
From Immunome, Inc.
Via Business Wire
Immunome Reports First Quarter 2025 Financial Results and Provides Business Update
From Immunome, Inc.
Via Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference
From Immunome, Inc.
Via Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
Immunome Reports Full Year 2024 Financial Results and Provides Business Update
From Immunome, Inc.
Via Business Wire
Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC
From Immunome, Inc.
Via Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
Immunome to Present at Upcoming March Conferences
From Immunome, Inc.
Via Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Immunome, Inc.
Via Business Wire
Immunome Announces Pricing of Upsized Public Offering of Common Stock
From Immunome, Inc.
Via Business Wire
Immunome Announces Proposed Public Offering of Common Stock
From Immunome, Inc.
Via Business Wire
Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
From Immunome, Inc.
Via Business Wire
Hummingbird Bioscience Licenses Novel Antibodies to Immunome
From Hummingbird Bioscience
Via GlobeNewswire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference
From Immunome, Inc.
Via Business Wire
Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update
From Immunome, Inc.
Via Business Wire
Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation Conference
From Immunome, Inc.
Via Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021
From Immunome, Inc.
Via Business Wire
Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium
From Immunome, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.